{"organizations": [], "uuid": "a603c343e450d32a242f452699ea8412f05ba61e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-announces-lon/brief-voyager-therapeutics-announces-longer-term-data-from-ongoing-phase-1b-trial-of-vy-aadc-for-advanced-parkinsons-disease-idUSASB0C9OB", "country": "US", "domain_rank": 408, "title": "BRIEF-Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-09T14:06:00.000+02:00", "replies_count": 0, "uuid": "a603c343e450d32a242f452699ea8412f05ba61e"}, "author": "", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-announces-lon/brief-voyager-therapeutics-announces-longer-term-data-from-ongoing-phase-1b-trial-of-vy-aadc-for-advanced-parkinsons-disease-idUSASB0C9OB", "ord_in_thread": 0, "title": "BRIEF-Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease", "locations": [], "entities": {"persons": [{"name": "parkinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "advanced parkinson’s disease reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 9, 2018 / 12:08 PM / Updated 10 minutes ago BRIEF-Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease Reuters Staff 1 Min Read March 9 (Reuters) - Voyager Therapeutics Inc: * VOYAGER THERAPEUTICS ANNOUNCES LONGER-TERM DATA FROM ONGOING PHASE 1B TRIAL OF VY-AADC FOR ADVANCED PARKINSON’S DISEASE * VOYAGER THERAPEUTICS - ‍PIVOTAL PHASE 2-3 PROGRAM REMAINS ON TRACK TO DOSE FIRST PATIENT MID-2018​ Source text for Eikon:  ", "external_links": [], "published": "2018-03-09T14:06:00.000+02:00", "crawled": "2018-03-09T14:31:44.031+02:00", "highlightTitle": ""}